key: cord-0966225-wx38b3cd authors: Shete, Anita; Mohandas, Sreelekshmy; Jain, Rajlaxmi; Yadav, Pragya D. title: A qualitative IgG ELISA for detection of SARS-CoV-2 specific antibodies in Syrian hamster serum samples date: 2021-05-10 journal: STAR Protoc DOI: 10.1016/j.xpro.2021.100573 sha: ea2767c0fafb6824eff212813c4f2309878d0fb0 doc_id: 966225 cord_uid: wx38b3cd This protocol describes an indirect enzyme-linked immunosorbent assay (ELISA) for qualitative detection of IgG antibodies against Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Syrian hamster serum samples. We describe the preparation of inactivated virus antigen and the negative control antigen, and the use of antigen-coated microtiter plates to detect SARS-CoV-2 specific antibodies from SARS-CoV-2-infected hamsters, including the criteria for differentiating positive vs negative reaction. The limited batch-to-batch variability of this assay has been verified with two batches of independently-prepared antigens. This protocol describes an indirect enzyme-linked immunosorbent assay (ELISA) for qualitative detection of IgG antibodies against Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in Syrian hamster serum samples. We describe the preparation of inactivated virus antigen and the negative control antigen, and the use of antigen-coated microtiter plates to detect SARS-CoV-2 specific antibodies from SARS-CoV-2-infected hamsters, including the criteria for differentiating positive vs negative reaction. The limited batch-to-batch variability of this assay has been verified with two batches of independently-prepared antigens. For complete details on the use and execution of this protocol, please refer to (Mohandas et al., 2021) . The present protocol was approved by Institutional Animal Ethical Committee of ICMR NIV, Pune and all the experiments involving animals were performed as per guidelines laid down by Committee for the Purpose of Control and Supervision of Experiments on animals, Government of India. Prepare virus stock antigens, gamma irradiation, and confirm inactivation of the virus stock as described below. Prepare Solutions following the recipes mentioned in the Materials and Equipment section. A complete list of reagents and resources required is given in the Key resources table. 1. Maintain African green monkey kidney cell line (Vero CCL-81) in Eagle's minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 mg /ml) 2. Infect the cells with SARS-CoV-2 isolate a. Infect the Vero CCL-81 cells (at 80-90% confluency, in 40 ml MEM, cultured in 225cm 2 tissue culture flasks) with 1ml virus isolate with Median Tissue Culture Infectious Dose (TCID50) of 10 6.5 /ml. Incubate in a CO2 incubator with 5% CO2 at 37°C for 4 days. b. On day 4 post inoculation, observe for the presence of cytopathic effects (CPE; Figure 1 ). c. Freeze the whole flask in -80°C, and then thaw it and harvest the entire volume of the tissue culture fluid (TCF; the supernatant from the culture) d. Centrifuge the TCF at 2490 g for 5 min at 4 °C e. After centrifugation, separate and store the clear supernatant at −80°C until further use. This is referred to as virus stock hereafter. f. Proceed to Gamma irradiation of the stock as described below 3. Preparation of the negative control antigen a. Incubate Vero CCL-81 cells in a CO2 incubator with 5% CO2 at 37°C for 4 days b. Repeat step 2b to 2e to prepare the negative control antigen stock c. Proceed to Gamma irradiation of the stock as described below 4. Gamma inactivation of virus stock and Vero CCL-81 control supernatant. a. Thaw the virus or the negative control antigen stock and place it on ice in a biohazard bag in the steel container of the gamma chamber b. Use a Co-60 source (Gamma Chamber; GC 5000) with a total radiation dose of 8 kiloGray (kGy) for inactivation of SARS-CoV-2, which can be achieved by exposing to gamma dose rate of 6.89 kGy for 1 hour 4 minutes Concentration of the antigen Timing: [1 day] 6. Add 40 ml of the inactivated antigen in sample reservoir of the Jumbosep centrifugal devices with 30K membrane insert. 7. Centrifuge for 12 minutes at 177 g at 4°C. 8. After centrifugation discard the filtrate collected in the filtrate receiver. 9. Collect approximately 35 ml of the sample retained (now referred as concentrated antigen) in the sample reservoir in a pre-chilled bottle. 10. Aliquot the concentrated antigen 1 ml/ vial and store at -80°C for further use. 11. Similarly, for preparation of concentrated negative control antigen, add 40 ml the control supernatant of Vero CCL-81 cells in separate Jumbosep centrifugal devices with 30K membrane insert and repeat steps 7 to 10. Estimate the total protein concentration by the Lowry's method (Lowry et al., 1951) . CRITICAL: Two separate Jumbosep centrifugal devices should be used for SARS-CoV-2 and negative control antigen preparation, respectively. Table REAGENT J o u r n a l P r e -p r o o f CRITICAL: Reagents should be used within the expiry. All the reagents should be opened in aseptic conditions. Wear protective gloves, clothing, and eye and face protection. Wash hands thoroughly after handling Sulfuric acid. Alternatives: Conjugate diluent (Stablizyme) can be replaced by the sample diluent at step number 8. Step 4. Prepare positive and negative controls for the assay a. Blood collection from hamsters: Anaesthetize the hamsters prior to blood collection using isoflurane. Perform blood collection (0.25 ml) through retroorbital route. Allow the blood sample to clot at room temperature for 30 minutes and centrifuge the sample at 177 g for 10 minutes to separate serum. Aliquot the separated serum and store it at -20°C. b. Collect positive serum from hamsters infected by SARS-CoV-2 virus and negative control serum from uninfected hamsters. (Mohandas et al., 2021) 5. Dilute hamster IgG positive and negative serum samples to be tested prior to initiating the test. a. Dilute the hamster sera to 1:100 with the sample diluent. 6. Add 100 μl of 1:100 diluted serum samples to the coated microtiter plate and incubate at 37°C for one hour. 7. After incubation, wash the plates three times with PBST. 8. Add 100 μl of anti-hamster IgG horseradish peroxidase (HRP; 1:3000 diluted with stabilzyme) per well and incubate the plate for one hour at 37°C. It is important to confirm the dilutions of the serum samples and conjugated antibodies 9. After incubation, wash the plates three times with PBST. 10. Add 100 μl of 3,3',5,5'-tetramethylbenzidine (TMB) substrate per well and incubate for 10 minutes at 25-28°C. This protocol allows qualitative detection of anti-SARS CoV-2 IgG antibodies in hamster serum samples. In our recent paper (Mohandas et al., 2021) , we have applied this IgG ELISA for the detection of SARS-CoV-2 specific antibodies in Syrian hamster serum samples. Three vaccine formulations were evaluated in this study. Serum IgG titers were also determined using this assay by testing 10-fold serial dilutions of each serum sample, starting from 1:100 dilution. Titer values were determined at the highest dilution when the optical density (OD) was more than 0.2 and positive/negative (P/N) ratio above 1.5. Robust anti SARS CoV-2 IgG antibody response was detected in this study against vaccine candidates with an increasing trend of OD of 0.84, 0.97, and 0.91 on 3, 7, and 15 days post infection, respectively (Figure 2) . Reproducibility of the assay has been checked using two different batches of the independently prepared concentrated antigens (Lot 4 vs Lot 7), and the results from the weak positive sera and the negative controls were found to be comparable between these two trials ( Figure 3 ; Table 1 ). a. OD of the sample is more than cut off b. P/N of the sample is more than 1.5. c. Ham-13 Day-10 is considered as positive as O.D is 0.364 which is > cut off (0.273) and P/N is 4.49 which is >1.5 It is an indirect IgG ELISA. The assay has been validated using the limited number of SARS CoV-2 infected Syrian hamsters (Mohandas et al., 2021) . The performance of the assay has not been optimized for visual determination. We have not tested the assay with other species of hamsters. We speculate that there may not be cross reactivity of the Goat anti-hamster IgG horseradish peroxidase (HRP) to other hamsters than Syrian hamsters Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr Pragya D Yadav (hellopragya22@gmail.com). All the newly generated materials associated with this protocol will be available, on request to Director, ICMR-National Institute of Virology, subject to fulfillment of institutional criteria for sharing. The datasets supporting the current study have not been deposited in a public repository but are available from the corresponding author on request. Protein measurement with the Folin phenol reagent Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model A simple method of estimating fifty per cent endpoints First isolation of SARS-CoV-2 from clinical samples in India Authors acknowledge the support received from the Dr. No conflict of interest exists among authors.